CLNN
Clene Inc.
Price Chart
Latest Quote
$6.01
+0.08 (+1.35%)
Current Price
| Previous Close | $5.93 |
| Open | $5.85 |
| Day High | $6.07 |
| Day Low | $5.80 |
| Volume | 66,245 |
Stock Information
| Shares Outstanding | 12.78M |
| Total Debt | $22.05M |
| Cash Equivalents | $5.94M |
| Revenue | $134K |
| Net Income | $-33.51M |
| Sector | Consumer Defensive |
| Industry | Packaged Foods |
| Market Cap | $76.80M |
| EPS (TTM) | $-3.25 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $90.86M |
| Sales | $134K |
| Income | $-33.51M |
| Book/sh | $-1.60 |
| Cash/sh | $0.46 |
| Employees | 76 |
Financial Ratios
| Quick Ratio | 1.40 |
| Current Ratio | 1.94 |
Returns & Margins
| ROA | -56.06% |
| Gross Margin | 82.84% |
| Operating Margin | -13740.00% |
Ownership
| Insider Ownership | 17.06% |
| Institutional Ownership | 20.44% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.36 |
| P/S | 573.12 |
| P/B | -3.76 |
Analyst Data
| Recommendation | none |
| Target Price | $32.20 |
Technical Indicators
| SMA20 | $6.02 |
| SMA50 | $6.33 |
| SMA200 | $6.56 |
| RSI | 38.10 |
| ATR | 0.3986 |
| Shares Float | 10.50M |
| Short Float | 11.78% |
| Short Ratio | 0.90 |
| Volatility | 0.92 |
| Rel Volume | 0.62 |
Performance History
| Week | +8.68% |
| Month | -5.80% |
| Quarter | +2.39% |
| 6 Months | -6.53% |
| YTD | +4.16% |
| Year | +42.08% |
| 3 Years | -71.65% |
| 5 Years | -97.30% |
| 10 Years | -96.92% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $6.01 | 66,200 |
| 2026-06-17 | $5.93 | 74,500 |
| 2026-06-16 | $5.85 | 190,000 |
| 2026-06-15 | $5.77 | 64,300 |
| 2026-06-12 | $5.84 | 78,500 |
| 2026-06-11 | $5.53 | 72,400 |
| 2026-06-10 | $5.50 | 125,400 |
| 2026-06-09 | $5.57 | 103,600 |
| 2026-06-08 | $5.33 | 87,000 |
| 2026-06-05 | $5.45 | 114,700 |
| 2026-06-04 | $5.82 | 59,700 |
| 2026-06-03 | $5.76 | 117,700 |
| 2026-06-02 | $5.87 | 155,200 |
| 2026-06-01 | $6.11 | 163,200 |
| 2026-05-29 | $6.56 | 76,700 |
| 2026-05-28 | $6.70 | 131,200 |
| 2026-05-27 | $6.69 | 94,700 |
| 2026-05-26 | $6.57 | 105,000 |
| 2026-05-22 | $6.70 | 106,500 |
| 2026-05-21 | $6.81 | 132,400 |
| 2026-05-20 | $6.90 | 116,500 |
| 2026-05-19 | $6.38 | 159,500 |
About Clene Inc.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene Inc. is headquartered in Salt Lake City, Utah.
đ° Latest News
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Zacks âĸ 2026-06-18T13:40:04Z
Clene (CLNN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Zacks âĸ 2026-06-04T13:55:03Z
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced
Simply Wall St. âĸ 2026-05-22T00:58:40Z
Are Medical Stocks Lagging BrightSpring Health Services, Inc. (BTSG) This Year?
Zacks âĸ 2026-05-19T13:40:02Z
3 Growth Stocks Insiders Are Betting On
Simply Wall St. âĸ 2026-05-18T17:35:40Z
Hennessy Capital Investment VII And 2 Insider-Favored Growth Stocks To Watch
Simply Wall St. âĸ 2026-05-18T11:35:48Z
Top Growth Companies With High Insider Ownership May 2026
Simply Wall St. âĸ 2026-05-15T17:35:44Z
3 High-Growth Insider-Owned Companies With Earnings Surging Up To 80%
Simply Wall St. âĸ 2026-05-15T11:35:42Z
3 Growth Companies With High Insider Ownership And Up To 71% Earnings Growth
Simply Wall St. âĸ 2026-05-14T17:36:05Z
Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-14T13:10:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $43,000 | $70,000 | $121,000 | $26,000 |
| Cost Of Revenue | $43,000 | $70,000 | $121,000 | $26,000 |
| Total Revenue | $200,000 | $342,000 | $654,000 | $473,000 |
| Operating Revenue | $200,000 | $342,000 | $654,000 | $473,000 |
| Expenses | ||||
| Interest Expense | $2,682,000 | $4,064,000 | $4,558,000 | $3,296,000 |
| Total Expenses | $22,016,000 | $32,317,000 | $38,914,000 | $45,030,000 |
| Other Income Expense | $-885,000 | $-3,466,000 | $-6,758,000 | $18,483,000 |
| Net Non Operating Interest Income Expense | $-3,472,000 | $-3,960,000 | $-4,486,000 | $-3,844,000 |
| Total Other Finance Cost | $1,013,000 | $761,000 | $1,317,000 | $773,000 |
| Interest Expense Non Operating | $2,682,000 | $4,064,000 | $4,558,000 | $3,296,000 |
| Operating Expense | $21,973,000 | $32,247,000 | $38,793,000 | $45,004,000 |
| Other Operating Expenses | $-612,000 | $-504,000 | $-963,000 | $-3,079,000 |
| General And Administrative Expense | $8,430,000 | $12,427,000 | $12,834,000 | $16,163,000 |
| Other Non Operating Income Expenses | - | $-2,255,000 | $-15,565,000 | $32,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-26,173,000 | $-39,400,000 | $-49,504,000 | $-29,918,000 |
| Net Interest Income | $-3,472,000 | $-3,960,000 | $-4,486,000 | $-3,844,000 |
| Interest Income | $223,000 | $865,000 | $1,389,000 | $225,000 |
| Normalized Income | $-25,288,000 | $-38,189,000 | $-58,311,000 | $-48,369,000 |
| Net Income From Continuing And Discontinued Operation | $-26,173,000 | $-39,400,000 | $-49,504,000 | $-29,918,000 |
| Total Operating Income As Reported | $-23,083,000 | $-33,093,000 | $-40,540,000 | $-48,409,000 |
| Net Income Common Stockholders | $-26,173,000 | $-39,400,000 | $-49,504,000 | $-29,918,000 |
| Net Income | $-26,173,000 | $-39,400,000 | $-49,504,000 | $-29,918,000 |
| Net Income Including Noncontrolling Interests | $-26,173,000 | $-39,400,000 | $-49,504,000 | $-29,918,000 |
| Net Income Continuous Operations | $-26,173,000 | $-39,400,000 | $-49,504,000 | $-29,918,000 |
| Pretax Income | $-26,173,000 | $-39,400,000 | $-49,504,000 | $-29,918,000 |
| Special Income Charges | $0 | $-129,000 | $2,470,000 | $18,282,000 |
| Interest Income Non Operating | $223,000 | $865,000 | $1,389,000 | $225,000 |
| Operating Income | $-21,816,000 | $-31,975,000 | $-38,260,000 | $-44,557,000 |
| Depreciation Amortization Depletion Income Statement | $144,000 | $266,000 | $267,000 | - |
| Depreciation And Amortization In Income Statement | $144,000 | $266,000 | $267,000 | - |
| Depreciation Income Statement | $144,000 | $266,000 | $267,000 | - |
| Gross Profit | $157,000 | $272,000 | $533,000 | $447,000 |
| Per Share | ||||
| Diluted EPS | $-2.65 | $-5.67 | $-9.43 | $-9.20 |
| Basic EPS | $-2.65 | $-5.67 | $-9.43 | $-9.20 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-21,111,000 | $-32,480,000 | $-52,048,000 | $-44,054,000 |
| Total Unusual Items | $-885,000 | $-1,211,000 | $8,807,000 | $18,451,000 |
| Total Unusual Items Excluding Goodwill | $-885,000 | $-1,211,000 | $8,807,000 | $18,451,000 |
| Reconciled Depreciation | $1,495,000 | $1,645,000 | $1,705,000 | $1,019,000 |
| EBITDA (Bullshit earnings) | $-21,996,000 | $-33,691,000 | $-43,241,000 | $-25,603,000 |
| EBIT | $-23,491,000 | $-35,336,000 | $-44,946,000 | $-26,622,000 |
| Diluted Average Shares | $9,858,907 | $6,954,133 | $5,246,941 | $3,260,233 |
| Basic Average Shares | $9,858,907 | $6,954,133 | $5,246,941 | $3,260,233 |
| Diluted NI Availto Com Stockholders | $-26,173,000 | $-39,400,000 | $-49,504,000 | $-29,918,000 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Restructuring And Mergern Acquisition | $0 | $-85,000 | $-2,470,000 | $-17,862,000 |
| Gain On Sale Of Security | $-885,000 | $-1,082,000 | $6,337,000 | $169,000 |
| Research And Development | $14,011,000 | $20,058,000 | $26,655,000 | $31,920,000 |
| Selling General And Administration | $8,430,000 | $12,427,000 | $12,834,000 | $16,163,000 |
| Other Gand A | $1,436,000 | $3,021,000 | $1,946,000 | $2,871,000 |
| Insurance And Claims | $725,000 | $822,000 | $1,593,000 | $3,395,000 |
| Salaries And Wages | $6,269,000 | $8,584,000 | $9,295,000 | $9,897,000 |
| Other Special Charges | - | $214,000 | - | $-420,000 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-17,592,000 | $-8,857,000 | $13,390,000 | $3,237,000 |
| Total Assets | $18,131,000 | $27,337,000 | $52,341,000 | $44,493,000 |
| Total Non Current Assets | $9,154,000 | $11,180,000 | $13,489,000 | $15,298,000 |
| Other Non Current Assets | $58,000 | $58,000 | $58,000 | $58,000 |
| Current Assets | $8,977,000 | $16,157,000 | $38,852,000 | $29,195,000 |
| Other Current Assets | $139,000 | $137,000 | $568,000 | $581,000 |
| Prepaid Assets | $3,022,000 | $3,406,000 | $1,909,000 | $2,290,000 |
| Inventory | $37,000 | $68,000 | $37,000 | $43,000 |
| Receivables | $590,000 | $391,000 | $1,338,000 | $2,966,000 |
| Taxes Receivable | $590,000 | $327,000 | $1,195,000 | $2,777,000 |
| Accounts Receivable | $0 | $64,000 | $143,000 | $189,000 |
| Cash Cash Equivalents And Short Term Investments | $5,189,000 | $12,155,000 | $35,000,000 | $23,315,000 |
| Cash And Cash Equivalents | $5,189,000 | $12,155,000 | $28,821,000 | $18,332,000 |
| Cash Equivalents | $2,211,000 | $7,002,000 | $24,997,000 | - |
| Cash Financial | $2,978,000 | $5,153,000 | $3,824,000 | - |
| Other Receivables | - | - | - | - |
| Debt | ||||
| Net Debt | $12,426,000 | $3,630,000 | - | $7,339,000 |
| Total Debt | $21,673,000 | $20,843,000 | $32,161,000 | $31,824,000 |
| Long Term Debt And Capital Lease Obligation | $16,791,000 | $19,558,000 | $12,055,000 | $24,844,000 |
| Long Term Debt | $13,541,000 | $15,426,000 | $7,152,000 | $19,253,000 |
| Current Debt And Capital Lease Obligation | $4,882,000 | $1,285,000 | $20,106,000 | $6,980,000 |
| Current Debt | $4,074,000 | $359,000 | $19,503,000 | $6,418,000 |
| Other Current Borrowings | $4,074,000 | $359,000 | $19,503,000 | $6,418,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $35,723,000 | $36,194,000 | $38,951,000 | $41,256,000 |
| Total Non Current Liabilities Net Minority Interest | $24,947,000 | $25,903,000 | $13,621,000 | $27,399,000 |
| Derivative Product Liabilities | $8,156,000 | $6,345,000 | $1,481,000 | $0 |
| Current Liabilities | $10,776,000 | $10,291,000 | $25,330,000 | $13,857,000 |
| Current Deferred Liabilities | $1,507,000 | $2,665,000 | $438,000 | $520,000 |
| Payables And Accrued Expenses | $1,251,000 | $2,262,000 | $2,666,000 | $4,870,000 |
| Payables | $892,000 | $1,240,000 | $1,504,000 | $3,014,000 |
| Accounts Payable | $892,000 | $1,240,000 | $1,504,000 | $3,014,000 |
| Other Non Current Liabilities | - | - | $85,000 | $2,555,000 |
| Equity | ||||
| Common Stock Equity | $-17,592,000 | $-8,857,000 | $13,390,000 | $3,237,000 |
| Total Equity Gross Minority Interest | $-17,592,000 | $-8,857,000 | $13,390,000 | $3,237,000 |
| Stockholders Equity | $-17,592,000 | $-8,857,000 | $13,390,000 | $3,237,000 |
| Gains Losses Not Affecting Retained Earnings | $172,000 | $71,000 | $199,000 | $203,000 |
| Other Equity Adjustments | $172,000 | $71,000 | $199,000 | $203,000 |
| Retained Earnings | $-308,296,000 | $-282,123,000 | $-242,723,000 | $-193,219,000 |
| Other | ||||
| Ordinary Shares Number | $10,849,974 | $8,089,565 | $6,421,142 | $3,737,979 |
| Share Issued | $10,849,974 | $8,089,565 | $6,421,142 | $3,737,979 |
| Tangible Book Value | $-17,592,000 | $-8,857,000 | $13,390,000 | $3,237,000 |
| Invested Capital | $23,000 | $6,928,000 | $40,045,000 | $28,908,000 |
| Working Capital | $-1,799,000 | $5,866,000 | $13,522,000 | $15,338,000 |
| Capital Lease Obligations | $4,058,000 | $5,058,000 | $5,506,000 | $6,153,000 |
| Total Capitalization | $-4,051,000 | $6,569,000 | $20,542,000 | $22,490,000 |
| Additional Paid In Capital | $290,531,000 | $273,194,000 | $255,913,000 | $196,246,000 |
| Capital Stock | $1,000 | $1,000 | $1,000 | $7,000 |
| Common Stock | $1,000 | $1,000 | $1,000 | $7,000 |
| Long Term Capital Lease Obligation | $3,250,000 | $4,132,000 | $4,903,000 | $5,591,000 |
| Current Deferred Revenue | $1,507,000 | $2,665,000 | $438,000 | $520,000 |
| Current Capital Lease Obligation | $808,000 | $926,000 | $603,000 | $562,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $3,136,000 | $4,079,000 | $2,120,000 | $2,007,000 |
| Current Accrued Expenses | $359,000 | $1,022,000 | $1,162,000 | $1,856,000 |
| Net PPE | $9,096,000 | $11,122,000 | $13,431,000 | $15,240,000 |
| Accumulated Depreciation | $-9,361,000 | $-7,876,000 | $-6,887,000 | $-5,273,000 |
| Gross PPE | $18,457,000 | $18,998,000 | $20,318,000 | $20,513,000 |
| Leases | $9,983,000 | $9,983,000 | $9,983,000 | $5,677,000 |
| Construction In Progress | $1,298,000 | $1,298,000 | $1,438,000 | $5,664,000 |
| Other Properties | $6,539,000 | $7,080,000 | $8,260,000 | $8,536,000 |
| Machinery Furniture Equipment | $637,000 | $637,000 | $637,000 | $636,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $14,000 | $15,000 | $14,000 | $14,000 |
| Raw Materials | $23,000 | $53,000 | $23,000 | $29,000 |
| Other Short Term Investments | - | $0 | $6,179,000 | $4,983,000 |
| Treasury Shares Number | - | - | $0 | - |
| Other Inventories | - | - | - | - |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-18,585,000 | $-21,341,000 | $-30,501,000 | $-44,190,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-18,546,000 | $-21,326,000 | $-30,171,000 | $-39,011,000 |
| Cash Flow From Continuing Operating Activities | $-18,546,000 | $-21,326,000 | $-30,171,000 | $-39,011,000 |
| Operating Gains Losses | $885,000 | $1,449,000 | $-6,337,000 | $-167,000 |
| Investing Activities | ||||
| Capital Expenditure | $-39,000 | $-15,000 | $-330,000 | $-5,179,000 |
| Investing Cash Flow | $-39,000 | $6,316,000 | $-1,499,000 | $-10,164,000 |
| Cash Flow From Continuing Investing Activities | $-39,000 | $6,316,000 | $-1,499,000 | $-10,164,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $10,402,000 | $9,243,000 | $42,094,000 | $11,460,000 |
| Financing Cash Flow | $11,518,000 | $-1,529,000 | $42,163,000 | $17,249,000 |
| Cash Flow From Continuing Financing Activities | $11,518,000 | $-1,529,000 | $42,163,000 | $17,249,000 |
| Net Common Stock Issuance | $10,402,000 | $9,243,000 | $42,094,000 | $11,460,000 |
| Common Stock Issuance | $10,402,000 | $9,243,000 | $42,094,000 | $11,460,000 |
| Net Other Financing Charges | - | - | $-200,000 | $-81,000 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-384,000 | $-20,820,000 | $-81,000 | $-135,000 |
| Issuance Of Debt | $1,500,000 | $9,924,000 | $350,000 | $5,695,000 |
| Interest Paid Supplemental Data | $1,043,000 | $2,613,000 | $3,059,000 | $2,320,000 |
| End Cash Position | $5,247,000 | $12,213,000 | $28,879,000 | $18,390,000 |
| Beginning Cash Position | $12,213,000 | $28,879,000 | $18,390,000 | $50,346,000 |
| Effect Of Exchange Rate Changes | $101,000 | $-127,000 | $-4,000 | $-30,000 |
| Changes In Cash | $-7,067,000 | $-16,539,000 | $10,493,000 | $-31,926,000 |
| Proceeds From Stock Option Exercised | $0 | $124,000 | $0 | $310,000 |
| Net Issuance Payments Of Debt | $1,116,000 | $-10,896,000 | $269,000 | $5,560,000 |
| Net Long Term Debt Issuance | $1,116,000 | $-10,896,000 | $269,000 | $5,560,000 |
| Long Term Debt Payments | $-384,000 | $-20,820,000 | $-81,000 | $-135,000 |
| Long Term Debt Issuance | $1,500,000 | $9,924,000 | $350,000 | $5,695,000 |
| Net Investment Purchase And Sale | $0 | $6,331,000 | $-1,169,000 | $-4,985,000 |
| Sale Of Investment | $0 | $12,500,000 | $5,000,000 | $19,629,000 |
| Purchase Of Investment | $0 | $-6,169,000 | $-6,169,000 | $-24,614,000 |
| Net PPE Purchase And Sale | $-39,000 | $-15,000 | $-330,000 | $-5,179,000 |
| Purchase Of PPE | $-39,000 | $-15,000 | $-330,000 | $-5,179,000 |
| Change In Working Capital | $-3,353,000 | $3,211,000 | $-191,000 | $-1,540,000 |
| Change In Other Current Liabilities | $-1,000,000 | $-421,000 | $-566,000 | $-493,000 |
| Change In Payables And Accrued Expense | $-2,567,000 | $3,782,000 | $-1,653,000 | $538,000 |
| Change In Accrued Expense | $-2,219,000 | $4,046,000 | $-143,000 | $253,000 |
| Change In Payable | $-348,000 | $-264,000 | $-1,510,000 | $285,000 |
| Change In Account Payable | $-348,000 | $-264,000 | $-1,510,000 | $285,000 |
| Change In Prepaid Assets | $119,000 | $-198,000 | $1,976,000 | $-1,443,000 |
| Change In Inventory | $31,000 | $-31,000 | $6,000 | $-2,000 |
| Change In Receivables | $64,000 | $79,000 | $46,000 | $-140,000 |
| Changes In Account Receivables | $64,000 | $79,000 | $46,000 | $-140,000 |
| Other Non Cash Items | $2,218,000 | $3,816,000 | $15,039,000 | $-16,918,000 |
| Stock Based Compensation | $6,382,000 | $7,953,000 | $9,117,000 | $8,513,000 |
| Depreciation Amortization Depletion | $1,495,000 | $1,645,000 | $1,705,000 | $1,019,000 |
| Depreciation And Amortization | $1,495,000 | $1,645,000 | $1,705,000 | $1,019,000 |
| Depreciation | $1,495,000 | $1,645,000 | $1,705,000 | $1,019,000 |
| Gain Loss On Investment Securities | $885,000 | $1,081,000 | $-6,337,000 | $-167,000 |
| Gain Loss On Sale Of PPE | $0 | $154,000 | $0 | - |
| Net Income From Continuing Operations | $-26,173,000 | $-39,400,000 | $-49,504,000 | $-29,918,000 |
| Change In Tax Payable | - | - | - | $0 |
| Change In Income Tax Payable | - | - | - | $0 |
| Change In Other Working Capital | - | - | - | - |
Fetched: 2026-06-17